• Je něco špatně v tomto záznamu ?

Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2-b]pyridazine Derivatives Identified by Scaffold Hopping

P. Břehová, E. Řezníčková, K. Škach, R. Jorda, M. Dejmek, V. Vojáčková, M. Šála, M. Kovalová, M. Dračínský, A. Dolníková, T. Strmeň, M. Kinnertová, K. Chalupský, A. Dvořáková, T. Gucký, H. Mertlíková Kaiserová, P. Klener, R. Nencka, V. Kryštof

. 2023 ; 66 (16) : 11133-11157. [pub] 20230803

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016512

FLT3 kinase is a potential drug target in acute myeloid leukemia (AML). Patients with FLT3 mutations typically have higher relapse rates and worse outcomes than patients without FLT3 mutations. In this study, we investigated the suitability of various heterocycles as central cores of FLT3 inhibitors, including thieno[3,2-d]pyrimidine, pyrazolo[1,5-a]pyrimidine, imidazo[4,5-b]pyridine, pyrido[4,3-d]pyrimidine, and imidazo[1,2-b]pyridazine. Our assays revealed a series of imidazo[1,2-b]pyridazines with high potency against FLT3. Compound 34f showed nanomolar inhibitory activity against recombinant FLT3-ITD and FLT3-D835Y (IC50 values 4 and 1 nM, respectively) as well as in the FLT3-ITD-positive AML cell lines MV4-11, MOLM-13, and MOLM-13 expressing the FLT3-ITD-D835Y mutant (GI50 values of 7, 9, and 4 nM, respectively). In contrast, FLT3-independent cell lines were much less sensitive. In vitro experiments confirmed suppression of FLT3 downstream signaling pathways. Finally, the treatment of MV4-11 xenograft-bearing mice with 34f at doses of 5 and 10 mg/kg markedly blocked tumor growth without any adverse effects.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016512
003      
CZ-PrNML
005      
20231026105748.0
007      
ta
008      
231013s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.3c00575 $2 doi
035    __
$a (PubMed)37535845
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Břehová, Petra $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16000 Prague, Czech Republic $1 https://orcid.org/000000015353889X
245    10
$a Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2-b]pyridazine Derivatives Identified by Scaffold Hopping / $c P. Břehová, E. Řezníčková, K. Škach, R. Jorda, M. Dejmek, V. Vojáčková, M. Šála, M. Kovalová, M. Dračínský, A. Dolníková, T. Strmeň, M. Kinnertová, K. Chalupský, A. Dvořáková, T. Gucký, H. Mertlíková Kaiserová, P. Klener, R. Nencka, V. Kryštof
520    9_
$a FLT3 kinase is a potential drug target in acute myeloid leukemia (AML). Patients with FLT3 mutations typically have higher relapse rates and worse outcomes than patients without FLT3 mutations. In this study, we investigated the suitability of various heterocycles as central cores of FLT3 inhibitors, including thieno[3,2-d]pyrimidine, pyrazolo[1,5-a]pyrimidine, imidazo[4,5-b]pyridine, pyrido[4,3-d]pyrimidine, and imidazo[1,2-b]pyridazine. Our assays revealed a series of imidazo[1,2-b]pyridazines with high potency against FLT3. Compound 34f showed nanomolar inhibitory activity against recombinant FLT3-ITD and FLT3-D835Y (IC50 values 4 and 1 nM, respectively) as well as in the FLT3-ITD-positive AML cell lines MV4-11, MOLM-13, and MOLM-13 expressing the FLT3-ITD-D835Y mutant (GI50 values of 7, 9, and 4 nM, respectively). In contrast, FLT3-independent cell lines were much less sensitive. In vitro experiments confirmed suppression of FLT3 downstream signaling pathways. Finally, the treatment of MV4-11 xenograft-bearing mice with 34f at doses of 5 and 10 mg/kg markedly blocked tumor growth without any adverse effects.
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a zvířata $7 D000818
650    12
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428
650    12
$a pyridaziny $x farmakologie $x terapeutické užití $7 D011724
650    12
$a akutní myeloidní leukemie $x patologie $7 D015470
650    _2
$a pyrimidiny $x farmakologie $7 D011743
650    _2
$a tyrosinkinasa 3 podobná fms $x genetika $7 D051941
650    _2
$a mutace $7 D009154
650    _2
$a apoptóza $7 D017209
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Řezníčková, Eva $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, 78371 Olomouc, Czech Republic $1 https://orcid.org/0000000347732850
700    1_
$a Škach, Kryštof $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16000 Prague, Czech Republic $1 https://orcid.org/0000000275586961
700    1_
$a Jorda, Radek $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, 78371 Olomouc, Czech Republic $1 https://orcid.org/0000000249057126 $7 xx0302156
700    1_
$a Dejmek, Milan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16000 Prague, Czech Republic $1 https://orcid.org/000000028195971X
700    1_
$a Vojáčková, Veronika $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, 78371 Olomouc, Czech Republic $1 https://orcid.org/0000000309463274
700    1_
$a Šála, Michal $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16000 Prague, Czech Republic
700    1_
$a Kovalová, Markéta $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, 78371 Olomouc, Czech Republic
700    1_
$a Dračínský, Martin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16000 Prague, Czech Republic
700    1_
$a Dolníková, Alexandra $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 12108 Prague, Czech Republic
700    1_
$a Strmeň, Timotej $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16000 Prague, Czech Republic
700    1_
$a Kinnertová, Monika $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, 78371 Olomouc, Czech Republic
700    1_
$a Chalupský, Karel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16000 Prague, Czech Republic
700    1_
$a Dvořáková, Alexandra $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16000 Prague, Czech Republic
700    1_
$a Gucký, Tomáš $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, 78371 Olomouc, Czech Republic
700    1_
$a Mertlíková Kaiserová, Helena $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16000 Prague, Czech Republic
700    1_
$a Klener, Pavel $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 12108 Prague, Czech Republic
700    1_
$a Nencka, Radim $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16000 Prague, Czech Republic
700    1_
$a Kryštof, Vladimír $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, 78371 Olomouc, Czech Republic $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 77900 Olomouc, Czech Republic $1 https://orcid.org/0000000158382118 $7 xx0097406
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 66, č. 16 (2023), s. 11133-11157
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37535845 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105743 $b ABA008
999    __
$a ok $b bmc $g 2000179 $s 1202874
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 66 $c 16 $d 11133-11157 $e 20230803 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
LZP    __
$a Pubmed-20231013
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace